A revolution in treatment of biliary disorders

Cellular therapy platform to repair and replace diseased tissues and organs

A leading biomedical company with expertise from the University of Cambridge

Bilitech is a bleeding edge biomedical technology company which leverages a cellular therapy platform in order to advance the huge potential of organoid technology in regenerative medicine.

The company’s technological calibre is underpinned by a sophisticated and experienced body of specialists with decades of experience in the biomedical sphere.

 

The Team

Dr Fotis Sampaziotis

Dr Fotis Sampaziotis

Chief Executive Officer

Fotios Sampaziotis is a physician hepatologist in the Cambridge University Hospitals liver Unit, a Clinical Lecturer at the University of Cambridge and a group leader at the Cambridge Stem Cell Institute. He is an internationally-recognised expert in organoid technology and has received multiple national and international awards including the Dame Sheila Sherlock award by the British Association for the Study of Liver Disease, the Medawar Medal by the British Transplantation Society and the Science and Sartorius prize for Regenerative Medicine. He is nominated a UK National Scholar by the United European Gastroenterology Association, he is a UK Research and Innovation council Future Leader Fellow and a founding member of the European Association for the Study of Liver Regenerative Hepatology Consortium. Fotios’s research focuses on regenerative medicine, bioengineering and biliary disorders.
Dr Kourosh Saeb-Parsy

Dr Kourosh Saeb-Parsy

Chief Medical Advisor

Kourosh is a liver, kidney and pancreas transplant surgeon and a research group leader at the University of Cambridge. He has extensive commercial experience and has worked at board level with multiple commercial organisations, from start-ups to multinationals. He has established several successful collaborative networks, creating synergy between clinical, academic and commercial organisations. His laboratory research interests are focused on the function, safety and immunogenicity of cellular therapies, including through the use of innovative experimental models. His clinical research is focused on improving outcomes after liver, kidney and pancreas transplantation.

Our Vision

Revolutionizing Primary Cell Culture

Harnessing organoid technology to deliver fully mature, minimally manipulated and genetically stable human cells in scalable organoid culture.

Setting New Standards In Organ Engineering

Pioneering organ engineering with BiliDuct™ – the first self-regenerating bioengineered organ structure.

Delivering Organoid-Based Therapy Solutions To Patients

Pushing the barriers of cell-based therapy with BiliCell™- the first organoid-based therapy proven to work in human organs.

Recent News

Lab-grown tissue repairs human organ for first time, Cambridge University scientists reveal

Cholangiocyte organoids can repair bile ducts after transplantation in the human liver

Cells grown in a laboratory could revive damaged livers

 

By Rhys Blakely

Publisher The Times

TheScientist News & Opinion: Organoids Repair Bile Ducts

 

By Abby Olena

Publisher The Scientist

Contact Us

8 + 15 =